Pharmaceutical care when using antidiarrheal microbial medicines for the correction of intestinal dysbiosis
DOI:
https://doi.org/10.24959/sphhcj.26.381Keywords:
antibiotic-associated diarrhea; antidiarrheal microbial medicines; intestinal dysbiosis; efficacy and safety of therapy; probiotics; prevention and treatment; pharmaceutical careAbstract
Intestinal dysbiosis is a pressing issue in modern medicine and pharmacy due to the high prevalence of intestinal microflora disorders among the population and their significant impact on overall health, well-being, and the effectiveness of treatment of concomitant diseases.
Aim. To assess the importance of pharmaceutical care as an effective mechanism for ensuring the effectiveness of antidiarrheal microbial medicines for the prevention and treatment of intestinal dysbiosis.
Materials and methods. The research materials were the questionnaire-based survey among 30 pharmacy visitors who applied to pharmacies to purchase antidiarrheal microbial medicines for the prevention and treatment of intestinal dysbiosis. The methodological basis of the study consists of the principles of objectivity and consistency. The work uses a set of general scientific and special methods, such as theoretical, generalization, data systematization, comparison, methods of studying literary sources, analysis, questionnaires, etc.
Results and discussion. To correct dysbacteriosis, respondents most often chose antidiarrheal microbial medicines based on lactobacilli and their combinations (Linex, Linex Forte, Lactovit Forte, Yoghurt) – 18 persons (60.00 %), Bacillus clausii (Enterozhermina) – 10 persons (33.30 %), and Saccharomyces boulardii (Enterol, Normagut) – 12 persons (40.00 %). Some pharmacy visitors combined different medicines to achieve the best pharmacotherapeutic results. Antidiarrheal microbial medicines in the dosage form of hard capsules were chosen by 20 respondents (66.70 %). For adults, this dosage form is more convenient and provides the stability of active microorganisms, as well as the ease of administration. Oral suspensions were used by 10 respondents (33.30 %), usually in cases of difficulties with swallowing capsules. The treatment compliance among respondents was generally high: 18 people (60.00 %) adhered strictly to the regimen, 9 persons (30.00 %) adhered moderately, and only 3 persons (10.00 %) showed low compliance, which was associated with forgetfulness or unauthorized changes to the course of treatment.
Conclusions. Providing proper pharmaceutical care is an effective mechanism for ensuring the effectiveness of anti-diarrheal microbial medicines for the prevention and treatment of intestinal dysbiosis. And the pharmacist, as an active participant in the pharmacotherapy of dysbacteriosis, is able to contribute to the prevention of dysbiotic manifestations, reduce the frequency and severity of dysbacteriosis, and improve the quality of life. The process of improving pharmaceutical care for intestinal dysbiosis should be ongoing, based on the latest technological solutions and scientifically sound approaches to the treatment of dysbiotic conditions, harmonized with the latest achievements in modern gastroenterology.
References
- Carías Domínguez, A. M., de Jesús Rosa Salazar, D., Stefanolo, J. P., Cruz Serrano, M. C., Casas, I. C., & Zuluaga Peña, J. R. (2025). Intestinal dysbiosis: Exploring definition, associated symptoms, and perspectives for a comprehensive understanding – A scoping review. Probiotics and Antimicrobial Proteins, 17(1), 440–449. https://doi.org/10.1007/s12602-024-10353-w
- Meng, X., Zhang, G., Cao, H., Yu, D., Fang, X., de Vos, W. M., & Wu, H. (2020). Gut dysbacteriosis and intestinal disease: Mechanism and treatment. Journal of Applied Microbiology, 129(4), 787–805. https://doi.org/10.1111/jam.14661
- Bidell, M. R., Hobbs, A. L. V., & Lodise, T. P. (2022). Gut microbiome health and dysbiosis: A clinical primer. Pharmacotherapy, 42(11), 849–857. https://doi.org/10.1002/phar.2731
- Perez, N. B., Dorsen, C., & Squires, A. (2020). Dysbiosis of the gut microbiome: A concept analysis. Journal of Holistic Nursing, 38(2), 223–232. https://doi.org/10.1177/0898010119879527
- Zhang, Y., Wang, H., Sang, Y., Liu, M., Wang, Q., Yang, H., & Li, X. (2024). Gut microbiota in health and disease: Advances and future prospects. MedComm, 5(12), e70012. https://doi.org/10.1002/mco2.70012
- Alagiakrishnan, K., Morgadinho, J., & Halverson, T. (2024). Approach to the diagnosis and management of dysbiosis. Frontiers in Nutrition, 11, 1330903. https://doi.org/10.3389/fnut.2024.1330903
- Guarner, F., Sanders, M. E., Szajewska, H., Cohen, H., Eliakim, R., Herrera-deGuise, C., Karakan, T., Merenstein, D., Piscoya, A., Ramakrishna, B., Salminen, S., & Melberg, J. (2024). World Gastroenterology Organisation global guidelines: Probiotics and prebiotics. Journal of Clinical Gastroenterology, 58(6), 533–553. https://doi.org/10.1097/MCG.0000000000002002
- Shen, Y., Fan, N., Ma, S. X., Cheng, X., Yang, X., & Wang, G. (2025). Gut microbiota dysbiosis: Pathogenesis, diseases, prevention, and therapy. MedComm, 6(5), e70168. https://doi.org/10.1002/mco2.70168
- Kompendium. Likarski preparaty. https://compendium.com.ua/uk/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026
This work is licensed under a Creative Commons Attribution 4.0 International License.
